医学新知2024,Vol.34Issue(5) :593-602.DOI:10.12173/j.issn.1004-5511.202401092

免疫检查点抑制剂在胶质母细胞瘤治疗中的研究进展

Research progress of immune checkpoint inhibitors in the treatment of glioblastoma

贾晓荣 张弓
医学新知2024,Vol.34Issue(5) :593-602.DOI:10.12173/j.issn.1004-5511.202401092

免疫检查点抑制剂在胶质母细胞瘤治疗中的研究进展

Research progress of immune checkpoint inhibitors in the treatment of glioblastoma

贾晓荣 1张弓1
扫码查看

作者信息

  • 1. 山西医科大学附属山西省人民医院放疗科(太原 030012)
  • 折叠

摘要

胶质母细胞瘤(glioblastoma,GBM)是中枢神经系统中最具侵袭性的神经胶质瘤,最大限度的手术切除、化疗、放疗是目前GBM的标准治疗手段,但由于中枢神经系统独特的免疫环境,导致免疫治疗在GBM中的应用面临重大挑战.目前免疫治疗策略以免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)为主,明确ICIs在GBM中的作用机制,开发有效的治疗靶点,对延长GBM患者的生存期具有重要意义.本研究对血脑屏障、肿瘤微环境、免疫细胞、ICIs及其联合疗法在GBM中的研究进展进行概述,以期为GBM免疫治疗提供参考.

Abstract

Glioblastoma(GBM)is the most invasive glioma in the central nervous system.Maximum surgical resection,chemotherapy and radiotherapy are currently the standard treatment for GBM.Due to the unique immune environment of the central nervous system,the application of immunotherapy in GBM is facing challenges.Immune checkpoint inhibitors(ICIs)is one of the main immunotherapy strategies for GBM.Clarifying the mechanism of ICIs in GBM and developing effective therapeutic targets are of great significance to prolong the survival of GBM patients.In the study,we summarize the research progress of blood-brain barrier,tumor microenvironment,immune cells,ICIs and their combination therapy in GBM to provide reference for GBM immunotherapy.

关键词

胶质母细胞瘤/免疫治疗/免疫细胞/免疫检查点抑制剂

Key words

Glioblastoma/Immunotherapy/Immunocyte/Immune checkpoint inhibitors

引用本文复制引用

基金项目

山西省科技厅优秀青年基金(201901D211524)

出版年

2024
医学新知
武汉大学中南医院,中国农工民主党湖北省委医药卫生工作委员会

医学新知

CSTPCD
影响因子:0.243
ISSN:1004-5511
参考文献量75
段落导航相关论文